Navigation Links
HeartWare Completes GLP Studies of Next Generation MVAD® Pump; Data Presented Today at ISRBP Congress
Date:9/9/2011

LOUISVILLE, Ky., Sept. 9, 2011 /PRNewswire/ -- Data presented today at the 19th Congress of the International Society for Rotary Blood Pumps (ISRBP) demonstrated that the HeartWare MVAD® Pump attained the objectives for system performance, hemocompatability and biocompatibility in Good Laboratory Practice (GLP) animal studies, a significant step prior to commencement of human clinical studies.

(Photo:  http://photos.prnewswire.com/prnh/20110909/LA65433)

HeartWare's MVAD Pump is a development-stage miniature ventricular assist device, approximately one-third the size of HeartWare's HVAD® Pump.  The MVAD is based on the same proprietary impeller suspension technology used in the HVAD Pump, with its single moving part held in place through a combination of passive-magnetic and hydrodynamic forces.  Like the HVAD Pump, the MVAD Pump is designed to support the heart's full cardiac output, yet also has the capability for partial support.

"The MVAD was successfully implanted via a left thoracotomy, without cardio-pulmonary bypass, and exhibited excellent blood handling characteristics during the course of the study," said Edwin C. McGee, Jr., M.D., Surgical Director, Heart Failure, Heart Transplantation, and Mechanical Assistance; Bluhm Cardiovascular Institute, Northwestern Memorial Hospital and Associate Professor, Northwestern University's Feinberg School of Medicine, Chicago.  "At the 90-day explant date, there was no evidence of device wear or thrombus, and end-organ gross and histological results were positive."

"We're pleased with these results and are appreciative of the efforts of Dr. McGee and our investigators," stated Doug Godshall, President and Chief Executive Officer of HeartWare International.  "Based on these successful outcomes, we remain on track to commence human clinical studies of the MVAD System, wi
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. HeartWare to Report 2010 Fourth Quarter and Year-End Financial Results
2. HeartWare to Present at the 22nd Annual Piper Jaffray Health Care Conference
3. HeartWare International, Inc. Temporary Suspension of Trading
4. U.S. Federal Trade Commission to Challenge Thoratecs Proposed Acquisition of HeartWare International
5. Enterologics Completes Acquisition of BioBalance Corp and Probiotic Product From New York Health Care, Inc
6. TWi Biotechnology Successfully Completes Patient Recruitment for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes
7. Kuros Completes Patient Recruitment in a Phase IIb Clinical Trial With KUR-211 for Diabetic Foot Ulcers
8. AMPAC Fine Chemicals Completes Contract Manufacturing Agreement for Smallpox Countermeasure API
9. Peloton Therapeutics Completes $18 Million Series A Financing
10. Sinapis Pharma Completes Phase I Trial
11. MiMedx Group Completes $5,000,000 Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... May 20, 2015 This year has ... for lawns. US Patented Pearl’s Premium Ultra Low ... around the country that are coming out of record ... a number of major global concerns related to water, ... grass – the alternative to the standard, water-wasting, chemical-treated ...
(Date:5/20/2015)... The global genotyping market is expected to grow at ... 2015 to 2020 to reach $17.0billion in 2020. Genotyping ... development process and to provide personalized therapy, factors that ... by key manufacturers to offer advanced and innovative products ... 113 market data tables & 37 figures spread through ...
(Date:5/20/2015)... 2015  Marc Tessier-Lavigne, president of The Rockefeller ... million from The Marie-Josée and Henry R. Kravis ... that will be the centerpiece of the University,s ... R. Kravis Research Building, two stories high, will ... three city blocks following the shoreline of the ...
(Date:5/20/2015)... 20, 2015  Resolution Bioscience announced today the successful ... TM , a blood-based liquid biopsy for an ALK-gene ... (NSCLC), the most common form of this cancer. Researchers ... patients to personalized therapies and direct them into clinical ... Department of Health, the CLIA authority in ...
Breaking Biology Technology:Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4Resolution Bioscience Receives CLIA Certification for its Diagnostic Laboratory and Launches CLIA-Certified Liquid Biopsy for Lung Cancer 2
... March 18 Johnson & Johnson,Pharmaceutical Research ... received an approvable letter from the U.S. ... Drug Application (NDA) for,ceftobiprole for the treatment ... diabetic foot infections., J&JPRD, along with ...
... 18 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,(TSX: ONC, NASDAQ: ... U.S. Patent 7,344,711 entitled "Use of Adenoviruses Mutated ... describe methods of treating,cancer using adenoviruses that are ... an activated Ras pathway., "This patent expands ...
... REDWOOD CITY, Calif., March 18 Ingenuity ... life science researchers, has,announced that they have ... GlaxoSmithKline for access to Ingenuity Pathways Analysis,(IPA) ... provide enterprise-wide,IPA access to researchers for rapid ...
Cached Biology Technology:FDA Issues Approvable Letter for Ceftobiprole for Treatment of Complicated Skin Infections 2Oncolytics Biotech Inc. Announces Issuance of 26th U.S. Patent 2Ingenuity Systems Extends Enterprise-Level Software Agreement With GlaxoSmithKline 2
(Date:5/11/2015)... , May 11, 2015  Through a well-rounded UAS delegation ... had a strong showing at AUVSI,s Unmanned 2015 conference ... of Ohio,s UAS industry met with ... from all points along the UAS ecosystem. ... (DDC) Vice President for Aerospace Rich Knoll . "If ...
(Date:5/8/2015)... JOSE, Calif. , May 8, 2015 Synaptics ... interface solutions, today announced that members of the executive management ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Waterfront Hotel in Boston, MA ... May 27, 2015 Time: 2:45pm ET Location: The New York ...
(Date:5/5/2015)... Conn. , May 5, 2015, NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, reminds ... Company,s Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS ... May 5-7, 2015. The three-day conference is ... David is speaking in is themed Global Fraud: Where ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Synaptics to Present at Upcoming Investor Conferences 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... Houston as a result of chemical pollution produced by manufacturing ... to a new study. But the new findings ... -- come with a catch, says a team of scientists ... CIRES, a joint institute of the University of Colorado at ...
... PARK, Md. - The University of Maryland, in partnership ... Maryland Baltimore County, has received a $7.9 million federal ... Resonance (NMR) magnet that will help researchers unravel the ... cancer, AIDS and other diseases. The grant is ...
... are reporting this week new study results they say provide ... from bone marrow for patients suffering from acute lung injury, ... intensive care units. Led by Drs. Michael A. Matthay ... the University of California, San Francisco, the team writes in ...
Cached Biology News:Texas petrochemical emissions down, but still underestimated, says study 2University of Maryland partnership receives $7.9M from NIH for superconducting research magnet 2University of Maryland partnership receives $7.9M from NIH for superconducting research magnet 3Using bone marrow stem cells to treat critically ill patients on verge of respiratory failure 2Using bone marrow stem cells to treat critically ill patients on verge of respiratory failure 3
Cross reactivity to St. Louis encephalitis (MSI-7) is determined by ELISA....
EGTA, 10 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
RABBIT ANTI HUMAN ATR (aa2122-2380) Immunogen: Human ATR peptide, amino acids 2122-2380...
casein kinase 2, alpha 1 polypeptide, transcript variant 2, mRNA (cDNA clone MGC:15232 IMAGE:4121882), complete cds...
Biology Products: